Observational, Safety Study of NovoNorm® (Repaglinide) and Insulin Analogue Combination Therapy in Type 2 Diabetes in Korea
Status:
Completed
Trial end date:
2013-03-01
Target enrollment:
Participant gender:
Summary
This trial is conducted in Asia. The primary objective of this study is to evaluate the
clinical safety profile during 26 weeks of NovoNorm® (repaglinide) and insulin analogue
combination therapy in type 2 diabetes under normal clinical practice conditions in Korea
while the secondary objective is to evaluate the safety and efficacy after 13 and 26 weeks of
NovoNorm® and insulin analogue combination therapy in type 2 diabetes under normal clinical
practice conditions in Korea.